What actually ends up in your GLP-1 monthly bill
New patients almost always underestimate the monthly cost of GLP-1 therapy because they anchor on the medication price alone. That number — the Wegovy or Zepbound copay, the LillyDirect vial, the compounded tirzepatide subscription — is only one of six recurring line items you should plan for. In an obesity-medicine practice or a telehealth program, the full stack typically breaks down like this:
- Medication — the largest line. $25–$550 with commercial insurance and a savings card, $349–$499 on LillyDirect self-pay, $299 on compounded semaglutide, $1,086–$1,349 at full list on Wegovy/Zepbound pens.
- Telehealth subscription — $99–$299/month at Hims, Ro, Henry, Found, Sequence (if the drug price above does not already include the visit).
- Provider visits — typically quarterly ($75–$300 per visit depending on copay and in-network status), sometimes monthly in the first year.
- Labs — lipid panel, A1C or fasting glucose, CMP with liver and kidney function, TSH baseline, B12 on maintenance. $150–$400/year with insurance, up to $800/year cash.
- Supplements — vitamin D3, B12 (especially on semaglutide), omega-3, electrolytes (LMNT/similar), protein powder. $30–$80/month if you are deliberate about it.
- Injection supplies — alcohol swabs, sharps container, BD insulin syringes if you are on compounded vials. $10–$25/month.
The real numbers for four common patient paths
Let us run the math for four realistic scenarios. (Treat these as ballparks — your copay, plan, and state pharmacy economics will vary.)
Path A: Commercial insurance covered, Wegovy $25 copay
- Drug: $25/mo
- Provider visits (quarterly): $75/mo (covered) → $25/mo prorated
- Labs: $15/mo (covered, annual deductible applies)
- Supplements: $40/mo
- Supplies: $0 (pen, not vial)
- Total: $105/mo, $1,260/yr, $6,300 over five years
Path B: Commercial denied, LillyDirect Zepbound vials
- Drug: $499/mo (10 mg vial; $349 at 2.5/5 mg)
- Telehealth: bundled with LillyDirect → $0 extra
- Provider visits: $50/mo (PCP for labs only)
- Labs: $20/mo (covered)
- Supplements: $40/mo
- Supplies: $15/mo (vials require syringes)
- Total: $624/mo, $7,488/yr, $37,440 over five years
Path C: Telehealth compounded semaglutide
- Drug + telehealth bundle (Hims/Henry/Ro): $199–$349/mo. Use $299.
- Provider visits: already bundled → $0 extra
- Labs: $25/mo (often required quarterly, paid out-of-pocket)
- Supplements: $40/mo
- Supplies: $15/mo
- Total: $379/mo, $4,548/yr, $22,740 over five years
Path D: Uninsured, Wegovy full list
- Drug: $1,349/mo
- Provider visits (quarterly cash): $83/mo prorated
- Labs cash: $50/mo
- Supplements: $40/mo
- Supplies: $0
- Total: $1,522/mo, $18,264/yr — not sustainable for most households
The five-year trap
The biggest financial mistake in this space is budgeting for a “weight-loss course” instead of a chronic medication. STEP 4 (withdrawal arm) showed that patients who stopped semaglutide regained roughly two-thirds of lost weight within a year. The FDA labels for Wegovy and Zepbound are explicit: “chronic weight management.” Plan for 5 years at minimum. If the Path B Zepbound LillyDirect budget of $624/month is not sustainable for 60 months, either the price path has to change (pursue prior auth, appeal, Manufacturers assistance program) or the dose has to change (maintenance at submaximal dose of 5 mg can be cheaper).
The trial-anchored efficacy per dollar
A budget conversation without efficacy anchors is incomplete. STEP 1 (Wilding et al., NEJM 2021, N=1,961) showed mean TBWL of 14.9% on semaglutide 2.4 mg over 68 weeks vs 2.4% on placebo. SURMOUNT-1 (Jastreboff et al., NEJM 2022, N=2,539) showed 22.5% on tirzepatide 15 mg over 72 weeks. SURMOUNT-5 (2025) head-to-head confirmed tirzepatide 15 mg beats semaglutide 2.4 mg on direct comparison. SELECT (Lincoff et al., NEJM 2023, N=17,604) showed 20% MACE reduction over ~40 months on semaglutide 2.4 mg in adults with established CVD — a non-weight value proposition that changes the budget conversation for that cohort. If you are in the SELECT population, a $625/month Zepbound budget versus a $105/month Wegovy budget is not just about weight — it is also about cardiovascular event reduction that has been trial-demonstrated for semaglutide, not tirzepatide (SURPASS-CVOT is still reading out). Drug choice and budget choice are linked.
The supplements most patients actually need
You will eat less on a GLP-1 — that is the point. Fewer calories means more marginal nutrients have to come from targeted supplementation:
- Vitamin D3: 2,000–4,000 IU/day. Many patients are already deficient at baseline and dietary intake drops further with reduced overall food volume.
- B12: 500–1,000 mcg/day methylcobalamin, especially if also on metformin (which reduces B12 absorption).
- Omega-3: 1–2 g combined EPA+DHA daily. Supports cardiovascular benefit layered onto the GLP-1 effect.
- Electrolytes: sodium, potassium, magnesium in packets (LMNT, Liquid IV zero-sugar, DIY). Critical during the first 8 weeks when fluid shifts can produce the “Ozempic fatigue” presentation.
- Protein powder: whey isolate or a good plant blend, 25–35 g per shake. Hitting 0.8–1.0 g/lb target protein on reduced appetite almost always requires shakes. See the protein target tool.
Prior auth and savings-card stacking — where the real money is
Nothing in your monthly budget will move as much as insurance status. A Wegovy prescription approved through commercial insurance with the Novo savings card caps at $0–$25/month for most covered patients; the same prescription denied and paid cash runs $1,349. Zepbound with the Lilly savings card similarly caps at $25 for covered patients and $550 for non-covered. Payer approval is the single largest lever. See the prior auth likelihood tool. If first-pass denial arrives, the appeal pathway matters: (1) read the denial letter carefully, (2) request peer-to-peer with a plan medical director, (3) file a formal internal appeal with added comorbidity documentation, (4) pursue external review if internal fails. A 2024 KFF analysis found ~50% of GLP-1 appeals overturn on peer-to-peer alone. Budget a 60–90 day window for this process and plan a bridge path (LillyDirect, NovoCare, or compounded) if you need therapy during the appeal.
Labs to pre-plan
Typical obesity-medicine lab cadence on a GLP-1:
- Baseline: A1C or fasting glucose, lipid panel, CMP, TSH, vitamin D 25-OH, B12 folate. $250–$400 cash / copay-only if insured.
- Month 3: A1C (if T2D), CMP. $40–$120.
- Month 6: A1C, lipid panel, CMP. $60–$180.
- Annually: full baseline panel plus DEXA if you want body composition tracking ($100–$250 cash).
If you are on a compounded telehealth service, they will often require you to upload lab results every 6 months as a condition of renewing the prescription. Build that into the budget.
Tax-advantaged dollars
Both HSAs and FSAs can reimburse GLP-1 medications when a physician has written a prescription for an eligible medical condition (obesity with BMI ≥ 30, or BMI ≥ 27 with comorbidity; type 2 diabetes). This includes compounded prescriptions from licensed pharmacies. For a 24% marginal-federal-bracket household, running $6,000/year through an HSA saves roughly $1,440 in federal income tax plus another $460 in FICA if you are W-2 employed — call it an effective ~30% discount on the pre-tax price. See the HSA/FSA GLP-1 calculator for the full arithmetic.
FAQ
What is the cheapest legitimate path in 2026?
If you have commercial insurance and the plan covers Wegovy or Zepbound with a savings card, your copay of $25–$50/month is unbeatable. If not, LillyDirect Zepbound vials at $349–$499/month are the cheapest path to an FDA-approved therapy. Compounded options ($249–$399/month) are cheaper but carry the caveats discussed in the compounded cost tool.
Does my HSA cover compounded tirzepatide?
Generally yes, when written as a prescription from a licensed clinician for an eligible condition. Save the prescription and pharmacy receipt.
Why does my “all-in” differ month to month?
Deductible resets in January typically spike month-1 costs. Quarterly provider visits cluster cost every 3rd month. Annual labs hit once. The annualized number in the calculator smooths this; your actual cash flow is lumpy.
How do I reduce a $600+/mo budget?
In order of impact: (1) appeal a PA denial; (2) ask the prescriber about a submaximal maintenance dose (5 mg tirzepatide vs 15 mg is often 40% cheaper on LillyDirect); (3) switch to a generic comorbidity med path to free HSA dollars; (4) reduce supplements to essentials; (5) compounded if and only if you can verify the pharmacy.
Can employers reimburse GLP-1 costs?
Yes — under section 213(d) medical expense definitions, employer reimbursement through an HRA or ICHRA can include GLP-1s. Large employers increasingly include GLP-1 coverage in their self-funded plans after 2024 union-negotiated carveouts; ask HR directly.
What if I have to stop the drug mid-year?
Your monthly burn falls to near zero, but STEP 4 showed patients regain roughly two-thirds of lost weight within 12 months of stopping. A realistic year-2 budget still includes quarterly visits, labs, and likely a restart attempt — do not plan a budget that assumes you stop permanently at month 12 unless your prescriber has a documented taper plan. See the stopping GLP-1 regain projector.
How do I plan for price changes?
Lilly cut LillyDirect Zepbound vials from $549 to $499 in late 2024 and added 2.5/5 mg pricing at $349. Novo matched with NovoCare Wegovy at $499. Medicare’s 2024 SELECT coverage was the first crack in the anorexiant exclusion. The Inflation Reduction Act’s Medicare price negotiation will likely reach semaglutide by 2028–2030. Budget at today’s number but recheck the path annually.